BAT8010 for Injection

DRUG2 trials

Sponsors

Bio-Thera Solutions

Conditions

Advanced Solid TumorsAdvanced or Metastatic Solid Tumors

Phase 1

Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients

CompletedNCT05848466

Bio-Thera SolutionsAdvanced or Metastatic Solid Tumors

Start: 2023-02-10End: 2025-06-06Updated: 2026-03-30

A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors

RecruitingNCT06376136

Bio-Thera SolutionsAdvanced Solid Tumors

Start: 2024-05-08End: 2026-12-09Target: 216Updated: 2025-08-13

Related Papers

A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the HER2-positive GC/GEJC cohort.

Journal of Clinical Oncology2026-05-28

A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the 1L HER2-positive breast cancer cohort.

Journal of Clinical Oncology2026-05-27